Early Renal Replacement Therapy in COVID 19 Patients With AKI Does it Improve the Outcome?
NCT ID: NCT05274685
Last Updated: 2022-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2021-06-01
2022-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Kidney Injury Risk in COVID-19
NCT04874779
Electronic Warning Systems in Diagnosis and Treatment of AKI
NCT03119480
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
NCT05805709
Search About Contributing Factors That Leading to Intradialytic Hypertension in Hemodialysis Patients
NCT07069491
Artificial Kidney Initiation in Kidney Injury
NCT01932190
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
covid positive with acute kidney injury receiving early renal replacement
haemodialysis
continuous venovenous hemodiafiltration (CVVHDF) at a prescribed dose of 30-35 mL/kg/h of effluent and with regional citrate anticoagulation
covid positive with acute kidney injury under conservative management
haemodialysis
continuous venovenous hemodiafiltration (CVVHDF) at a prescribed dose of 30-35 mL/kg/h of effluent and with regional citrate anticoagulation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
haemodialysis
continuous venovenous hemodiafiltration (CVVHDF) at a prescribed dose of 30-35 mL/kg/h of effluent and with regional citrate anticoagulation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Immuno-deficiency diseases.
* Chronic diabetic, cardiac and hypertensive patients
* autoimmune diseases.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Islam Mokhtar Ahmed
lecturer of anesthesia and intensive care
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine, Sohag University
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
soh-Med-22-2-24
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.